Terns Pharmaceuticals Inc
TERN39.900USD
+0.080+0.20%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
3.49BMarket Cap
LossP/E TTM
More Details of Terns Pharmaceuticals Inc Company
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Terns Pharmaceuticals Inc Info
Ticker SymbolTERN
Company nameTerns Pharmaceuticals Inc
IPO dateFeb 05, 2021
CEOBurroughs (Amy L)
Number of employees59
Security typeOrdinary Share
Fiscal year-endFeb 05
Address1065 East Hillsdale Blvd., Suite 100
CityFOSTER CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94404
Phone16505255535
Websitehttps://ternspharma.com/
Ticker SymbolTERN
IPO dateFeb 05, 2021
CEOBurroughs (Amy L)
Company Executives of Terns Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Ms. Sun (Melita) Jung
Ms. Sun (Melita) Jung
Chief Business Officer
Chief Business Officer
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Dr. Emil T. Kuriakose, M.D.
Dr. Emil T. Kuriakose, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Independent Director
Independent Director
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Andrew W. Gengos
Mr. Andrew W. Gengos
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Ms. Sun (Melita) Jung
Ms. Sun (Melita) Jung
Chief Business Officer
Chief Business Officer
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Nov 19
Updated: Wed, Nov 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Soleus Capital Management, L.P.
7.65%
Morgan Stanley & Co. LLC
7.10%
Deep Track Capital LP
7.06%
Vivo Capital, LLC
6.49%
Commodore Capital LP
5.37%
Other
66.33%
Shareholders
Shareholders
Proportion
Soleus Capital Management, L.P.
7.65%
Morgan Stanley & Co. LLC
7.10%
Deep Track Capital LP
7.06%
Vivo Capital, LLC
6.49%
Commodore Capital LP
5.37%
Other
66.33%
Shareholder Types
Shareholders
Proportion
Hedge Fund
32.08%
Investment Advisor
19.65%
Investment Advisor/Hedge Fund
13.02%
Research Firm
8.39%
Venture Capital
6.62%
Private Equity
3.70%
Individual Investor
0.24%
Bank and Trust
0.13%
Pension Fund
0.07%
Other
16.09%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
346
91.95M
105.09%
-23.09M
2025Q2
344
88.08M
100.66%
-23.35M
2025Q1
352
90.67M
103.82%
-24.88M
2024Q4
339
91.95M
108.28%
-13.40M
2024Q3
310
84.11M
100.51%
-7.48M
2024Q2
277
70.14M
99.60%
-17.86M
2024Q1
253
68.60M
105.57%
-10.37M
2023Q4
237
68.12M
109.36%
-7.25M
2023Q3
218
65.97M
109.78%
-9.89M
2023Q2
209
62.15M
110.88%
-6.45M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Soleus Capital Management, L.P.
8.17M
9.33%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
6.26M
7.15%
+104.53K
+1.70%
Jun 30, 2025
Deep Track Capital LP
7.50M
8.56%
+1.92M
+34.40%
Jun 30, 2025
Vivo Capital, LLC
6.90M
7.88%
--
--
Jun 30, 2025
Commodore Capital LP
4.65M
5.31%
+4.65M
--
Sep 09, 2025
BlackRock Institutional Trust Company, N.A.
4.98M
5.69%
-140.16K
-2.74%
Jun 30, 2025
The Vanguard Group, Inc.
4.31M
4.92%
+154.01K
+3.71%
Jun 30, 2025
Adage Capital Management, L.P.
1.28M
1.46%
+1.28M
--
Jun 30, 2025
OrbiMed Advisors, LLC
7.56M
8.64%
--
--
Jun 30, 2025
Candriam Luxembourg S.A.
2.88M
3.29%
--
--
Aug 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Roundhill GLP-1 & Weight Loss ETF
2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.44%
Virtus LifeSci Biotech Clinical Trials ETF
1.42%
State Street SPDR S&P Pharmaceuticals ETF
0.83%
Tema Oncology ETF
0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
0.39%
ALPS Medical Breakthroughs ETF
0.3%
ProShares Ultra Nasdaq Biotechnology
0.3%
iShares Russell 2000 Value ETF
0.13%
iShares Micro-Cap ETF
0.11%
View more
Roundhill GLP-1 & Weight Loss ETF
Proportion2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.44%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.42%
State Street SPDR S&P Pharmaceuticals ETF
Proportion0.83%
Tema Oncology ETF
Proportion0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.39%
ALPS Medical Breakthroughs ETF
Proportion0.3%
ProShares Ultra Nasdaq Biotechnology
Proportion0.3%
iShares Russell 2000 Value ETF
Proportion0.13%
iShares Micro-Cap ETF
Proportion0.11%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Terns Pharmaceuticals Inc?
The top five shareholders of Terns Pharmaceuticals Inc are:
Soleus Capital Management, L.P. holds 8.17M shares, accounting for 9.33% of the total shares.
Morgan Stanley & Co. LLC holds 6.26M shares, accounting for 7.15% of the total shares.
Deep Track Capital LP holds 7.50M shares, accounting for 8.56% of the total shares.
Vivo Capital, LLC holds 6.90M shares, accounting for 7.88% of the total shares.
Commodore Capital LP holds 4.65M shares, accounting for 5.31% of the total shares.
Soleus Capital Management, L.P. holds 8.17M shares, accounting for 9.33% of the total shares.
Morgan Stanley & Co. LLC holds 6.26M shares, accounting for 7.15% of the total shares.
Deep Track Capital LP holds 7.50M shares, accounting for 8.56% of the total shares.
Vivo Capital, LLC holds 6.90M shares, accounting for 7.88% of the total shares.
Commodore Capital LP holds 4.65M shares, accounting for 5.31% of the total shares.
What are the top three shareholder types of Terns Pharmaceuticals Inc?
The top three shareholder types of Terns Pharmaceuticals Inc are:
Soleus Capital Management, L.P.
Morgan Stanley & Co. LLC
Deep Track Capital LP
Soleus Capital Management, L.P.
Morgan Stanley & Co. LLC
Deep Track Capital LP
How many institutions hold shares of Terns Pharmaceuticals Inc (TERN)?
As of 2025Q3, 346 institutions hold shares of Terns Pharmaceuticals Inc, with a combined market value of approximately 91.95M, accounting for 105.09% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 4.43%.
What is the biggest source of revenue for Terns Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Terns Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
